{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:55:56Z","timestamp":1760784956436,"version":"build-2065373602"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008856","name":"Health and Family Planning Commission of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jsbmb.2021.105848","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T08:05:16Z","timestamp":1613721916000},"page":"105848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Selective degradation of the estrogen receptor in the treatment of cancers"],"prefix":"10.1016","volume":"209","author":[{"given":"Zunyuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengrong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.beem.2015.04.008","article-title":"Estrogen receptor alpha and beta in health and disease","volume":"29","author":"Jia","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0010","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1152\/physrev.2001.81.4.1535","article-title":"Mechanisms of estrogen action","volume":"81","author":"Nilsson","year":"2001","journal-title":"Physiol. Rev."},{"issue":"6","key":"10.1016\/j.jsbmb.2021.105848_bib0015","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1124\/mi.5.6.7","article-title":"Coregulators in nuclear estrogen receptor action: from concept to therapeutic targeting","volume":"5","author":"Hall","year":"2005","journal-title":"Mol. Interv."},{"issue":"12","key":"10.1016\/j.jsbmb.2021.105848_bib0020","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1073\/pnas.93.12.5925","article-title":"Cloning of a novel receptor expressed in rat prostate and ovary","volume":"93","author":"Kuiper","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0025","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00795-010-0514-3","article-title":"Mechanisms of estrogen receptor-\u03b1 upregulation in breast cancers","volume":"43","author":"Miyoshi","year":"2010","journal-title":"Med. Mol. Morphol."},{"issue":"15","key":"10.1016\/j.jsbmb.2021.105848_bib0030","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/cncr.32976","article-title":"The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer","volume":"126","author":"Ma","year":"2020","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jsbmb.2021.105848_bib0035","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/01635581.2020.1743871","article-title":"Synergistic cytotoxic and apoptotic effects of local probiotic lactobacillus brevis isolated from regional dairy products in combination with tamoxifen","volume":"73","author":"Nasiri","year":"2021","journal-title":"Nutr. Cancer"},{"issue":"1","key":"10.1016\/j.jsbmb.2021.105848_bib0040","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1039\/C6MD00553E","article-title":"Design and synthesis of novel selective estrogen receptor degradation inducers based on the diphenylheptane skeleton","volume":"8","author":"Misawa","year":"2016","journal-title":"Medchemcomm."},{"issue":"5","key":"10.1016\/j.jsbmb.2021.105848_bib0045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/CCO.0000000000000567","article-title":"Selective oestrogen receptor degraders in breast cancer: a review and perspectives","volume":"31","author":"Gombos","year":"2019","journal-title":"Curr. Opin. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.jsbmb.2021.105848_bib0050","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.bjc.6601629","article-title":"Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action","volume":"90","author":"Osborne","year":"2004","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.jsbmb.2021.105848_bib0055","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1758834017711097","article-title":"Fulvestrant in advanced breast cancer: evidence to date and place in therapy","volume":"9","author":"Bo\u00e9r","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"11","key":"10.1016\/j.jsbmb.2021.105848_bib0060","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/0008-5472.CAN-15-2357","article-title":"AZD9496: an oral estrogen receptor inhibitor that blocks the growth of ER-Positive and ESR1-Mutant breast tumors in preclinical models","volume":"76","author":"Weir","year":"2016","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.jsbmb.2021.105848_bib0065","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.5b00054","article-title":"Identification of GDC-0810 (ARN-810), an Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) that demonstrates robust activity in tamoxifen-resistant breast cancer xenografts","volume":"58","author":"Lai","year":"2015","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.jsbmb.2021.105848_bib0070","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1158\/1078-0432.CCR-16-2561","article-title":"Elacestrant (RAD1901), a Selective Estrogen Receptor Degrader (SERD), has antitumor activity in multiple er+ breast cancer patient-derived xenograft models","volume":"23","author":"Bihani","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2021.105848_bib0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bmcl.2013.11.078","article-title":"Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator","volume":"24","author":"Shoda","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0080","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1210\/en.2018-01095","article-title":"Next-generation ER\u03b1 inhibitors for endocrine-resistant ER+ breast Cancer","volume":"160","author":"Fanning","year":"2019","journal-title":"Endocrinology"},{"issue":"20","key":"10.1016\/j.jsbmb.2021.105848_bib0085","doi-asserted-by":"crossref","first-page":"5602","DOI":"10.1158\/0008-5472.CAN-17-1265","article-title":"Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors","volume":"77","author":"Zhao","year":"2017","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2021.105848_bib0090","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/acsmedchemlett.8b00414","article-title":"Maximizing ER-\u03b1 degradation maximizes activity in a tamoxifen-resistant breast Cancer model: identification of GDC-0927","volume":"10","author":"Kahraman","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"24","key":"10.1016\/j.jsbmb.2021.105848_bib0095","doi-asserted-by":"crossref","first-page":"11301","DOI":"10.1021\/acs.jmedchem.9b01580","article-title":"Design and synthesis of basic selective estrogen receptor degraders for endocrine therapy resistant breast Cancer","volume":"62","author":"Lu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jsbmb.2021.105848_bib0100","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1021\/acs.jmedchem.9b01293","article-title":"Discovery of SAR439859, a potent and selective estrogen receptor degrader (SERD) for the treatment of estrogen-receptor-Positive breast Cancer","volume":"63","author":"El-Ahmad","year":"2020","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.jsbmb.2021.105848_bib0105","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1399-3011.2004.00126.x","article-title":"The coactivator LXXLL nuclear receptor recognition motif","volume":"63","author":"Savkur","year":"2004","journal-title":"J. Pept. Res."},{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0110","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/cmdc.201000507","article-title":"Discovering small-molecule estrogen receptor \u03b1\/coactivator binding inhibitors: high-throughput screening, ligand development, and models for enhanced potency","volume":"6","author":"Sun","year":"2011","journal-title":"ChemMedChem."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0115","doi-asserted-by":"crossref","first-page":"e26857","DOI":"10.7554\/eLife.26857","article-title":"Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers","volume":"6","author":"Raj","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.jsbmb.2021.105848_bib0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13058-019-1227-8","article-title":"Estrogen receptor coregulator binding modulator (ERX-11) enhances the activity of CDK4\/6 inhibitors against estrogen receptor-positive breast cancers","volume":"21","author":"Viswanadhapalli","year":"2019","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.jsbmb.2021.105848_bib0125","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.3390\/ijms21124193","article-title":"Computer-aided ligand discovery for estrogen receptor alpha","volume":"21","author":"Bafna","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"15","key":"10.1016\/j.jsbmb.2021.105848_bib0130","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0135","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-019-0101-6","article-title":"PROTACs: great opportunities for academia and industry","volume":"4","author":"Sun","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"issue":"12","key":"10.1016\/j.jsbmb.2021.105848_bib0140","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1074\/mcp.T300009-MCP200","article-title":"Development of Protacs to target cancer-promoting proteins for ubiquitination and degradation","volume":"2","author":"Sakamoto","year":"2003","journal-title":"Mol. Cell Proteomics"},{"issue":"7","key":"10.1016\/j.jsbmb.2021.105848_bib0145","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2174\/1386207043328364","article-title":"Targeted degradation of proteins by small molecules: a novel tool for functional proteomics","volume":"7","author":"Zhang","year":"2004","journal-title":"Comb. Chem. High Throughput Screen."},{"issue":"3","key":"10.1016\/j.jsbmb.2021.105848_bib0150","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.bmcl.2003.11.042","article-title":"Degradation of target protein in living cells by small-molecule proteolysis inducer","volume":"14","author":"Zhang","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.jsbmb.2021.105848_bib0155","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/j.bmcl.2005.04.008","article-title":"Use of PROTACS as molecular probes of angiogenesis","volume":"15","author":"Bargagna-Mohan","year":"2005","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.jsbmb.2021.105848_bib0160","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1021\/ja039025z","article-title":"Chemical genetic control of protein levels: selective in vivo targeted degradation","volume":"126","author":"Schneekloth","year":"2004","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.jsbmb.2021.105848_bib0165","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1002\/cmdc.201000146","article-title":"Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs","volume":"5","author":"Cyrus","year":"2010","journal-title":"ChemMedChem."},{"issue":"11","key":"10.1016\/j.jsbmb.2021.105848_bib0170","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/cbic.201000222","article-title":"Two-headed PROTAC: an effective new tool for targeted protein degradation","volume":"11","author":"Cyrus","year":"2010","journal-title":"Chembiochem"},{"issue":"2","key":"10.1016\/j.jsbmb.2021.105848_bib0175","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1039\/C0MB00074D","article-title":"Impact of linker length on the activity of PROTACs","volume":"7","author":"Cyrus","year":"2011","journal-title":"Mol. Biosyst."},{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0180","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1021\/acschembio.6b01068","article-title":"Proteolysis-targeting chimeras: induced protein degradation as a therapeutic strategy","volume":"12","author":"Ottis","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2021.105848_bib0185","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/cbf.3369","article-title":"The PROTAC technology in drug development","volume":"37","author":"Zou","year":"2019","journal-title":"Cell Biochem. Funct."},{"issue":"3","key":"10.1016\/j.jsbmb.2021.105848_bib0190","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1021\/acschembio.7b00985","article-title":"Development of stabilized peptide-based PROTACs against estrogen receptor \u03b1","volume":"13","author":"Jiang","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111967","article-title":"Development of cell-permeable peptide-based PROTACs targeting estrogen receptor \u03b1","volume":"187","author":"Dai","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"22","key":"10.1016\/j.jsbmb.2021.105848_bib0200","doi-asserted-by":"crossref","first-page":"5904","DOI":"10.1016\/j.bmcl.2008.07.114","article-title":"Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics","volume":"18","author":"Schneekloth","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0205","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.csbj.2019.01.006","article-title":"Bivalent ligands for protein degradation in drug discovery","volume":"17","author":"Scheepstra","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"issue":"3","key":"10.1016\/j.jsbmb.2021.105848_bib0210","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.jsbmb.2021.105848_bib0215","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1021\/acsmedchemlett.9b00397","article-title":"PROTAC-mediated degradation of estrogen receptor in the treatment of Cancer","volume":"10","author":"Kargbo","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0220","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS18-P5-04-18","article-title":"Abstract P5-04-18: ARV-471, an oral estrogen receptor PROTAC degrader for breast cancer","volume":"79","author":"Flanagan","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jsbmb.2021.105848_bib0225","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","article-title":"Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy","volume":"13","author":"Li","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"16","key":"10.1016\/j.jsbmb.2021.105848_bib0230","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1021\/ja100691p","article-title":"Protein knockdown using methyl bestatin-ligand hybrid molecules: design and synthesis of inducers of ubiquitination-mediated degradation of cellular retinoic acid-binding proteins","volume":"132","author":"Itoh","year":"2010","journal-title":"J. Am. Chem. Soc."},{"issue":"22","key":"10.1016\/j.jsbmb.2021.105848_bib0235","doi-asserted-by":"crossref","first-page":"6768","DOI":"10.1016\/j.bmc.2011.09.041","article-title":"Design, synthesis and biological evaluation of nuclear receptor-degradation inducers","volume":"19","author":"Itoh","year":"2011","journal-title":"Bioorg. Med. Chem."},{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0240","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.bmcl.2011.11.086","article-title":"Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy","volume":"22","author":"Demizu","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"11","key":"10.1016\/j.jsbmb.2021.105848_bib0245","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1111\/cas.12272","article-title":"Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells","volume":"104","author":"Okuhira","year":"2013","journal-title":"Cancer Sci."},{"issue":"11","key":"10.1016\/j.jsbmb.2021.105848_bib0250","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1074\/jbc.M116.768853","article-title":"In vivo knockdown of pathogenic proteins via specific and nongenetic Inhibitor of Apoptosis Protein (IAP)-dependent Protein Erasers (SNIPERs)","volume":"292","author":"Ohoka","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.jsbmb.2021.105848_bib0255","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1021\/jm0204800","article-title":"Bridged bicyclic cores containing a 1,1-diarylethylene motif are high-affinity subtype-selective ligands for the estrogen receptor","volume":"46","author":"Muthyala","year":"2003","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.jsbmb.2021.105848_bib0260","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1021\/acsmedchemlett.8b00106","article-title":"New class of Selective Estrogen Receptor Degraders (SERDs): expanding the toolbox of PROTAC Degrons","volume":"9","author":"Wang","year":"2018","journal-title":"ACS Med. Chem. Lett."},{"issue":"6448","key":"10.1016\/j.jsbmb.2021.105848_bib0265","doi-asserted-by":"crossref","first-page":"eaaw4912","DOI":"10.1126\/science.aaw4912","article-title":"A glycine-specific N-degron pathway mediates the quality control of protein N-myristoylation","volume":"365","author":"Timms","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jsbmb.2021.105848_bib0270","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejmech.2019.03.058","article-title":"Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs)","volume":"172","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"43","key":"10.1016\/j.jsbmb.2021.105848_bib0275","doi-asserted-by":"crossref","first-page":"8692","DOI":"10.1039\/c2ob26531a","article-title":"Bicyclic core estrogens as full antagonists: synthesis, biological evaluation and structure-activity relationships of estrogen receptor ligands based on bridged oxabicyclic core arylsulfonamides","volume":"10","author":"Zhu","year":"2012","journal-title":"Org. Biomol. Chem."},{"issue":"41","key":"10.1016\/j.jsbmb.2021.105848_bib0280","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1074\/jbc.AC119.010790","article-title":"A modular PROTAC design for target destruction using a degradation signal based on a single amino acid","volume":"294","author":"Shanmugasundaram","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.jsbmb.2021.105848_bib0285","doi-asserted-by":"crossref","first-page":"E4068","DOI":"10.3390\/ijms21114068","article-title":"Global view of candidate therapeutic target genes in hormone-responsive breast Cancer","volume":"21","author":"Salvati","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.jsbmb.2021.105848_bib0290","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41556-020-0514-z","article-title":"Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance","volume":"22","author":"Bi","year":"2020","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112689","article-title":"Targeting estrogen receptor \u03b1 for degradation with PROTACs: a promising approach to overcome endocrine resistance","volume":"206","author":"Lin","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.jsbmb.2021.105848_bib0300","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1073\/pnas.89.9.4037","article-title":"Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover","volume":"89","author":"Dauvois","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U S A."},{"issue":"5","key":"10.1016\/j.jsbmb.2021.105848_bib0305","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/ijc.32020","article-title":"Molecular mechanisms of resistance to CDK4\/6 inhibitors in breast cancer: a review","volume":"145","author":"Pandey","year":"2019","journal-title":"Int. J. Cancer"},{"issue":"9","key":"10.1016\/j.jsbmb.2021.105848_bib0310","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrg3978","article-title":"Knocking down disease: a progress report on siRNA therapeutics","volume":"16","author":"Wittrup","year":"2015","journal-title":"Nat. Rev. Genet."},{"issue":"2","key":"10.1016\/j.jsbmb.2021.105848_bib0315","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrd.2016.238","article-title":"Cornerstones of CRISPR-Cas in drug discovery and therapy","volume":"16","author":"Fellmann","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0320","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.csbj.2019.01.006","article-title":"Bivalent ligands for protein degradation in drug discovery","volume":"17","author":"Scheepstra","year":"2019","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0325","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41421-018-0079-1","article-title":"A chemical approach for global protein knockdown from mice to non-human primates","volume":"5","author":"Sun","year":"2019","journal-title":"Cell Discov."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0330","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ebiom.2018.09.005","article-title":"Small-molecule PROTACs: an emerging and promising approach for the development of targeted therapy drugs","volume":"36","author":"An","year":"2018","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.jsbmb.2021.105848_bib0335","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nchembio.597","article-title":"Small-molecule hydrophobic tagging-induced degradation of HaloTag fusion proteins","volume":"7","author":"Neklesa","year":"2011","journal-title":"Nat. Chem. Biol."},{"issue":"21","key":"10.1016\/j.jsbmb.2021.105848_bib0340","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/acs.jmedchem.9b00846","article-title":"Simple structural modifications converting a bona fide MDM2 PROTAC degrader into a molecular glue molecule: a cautionary tale in the design of PROTAC degraders","volume":"62","author":"Yang","year":"2019","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.jsbmb.2021.105848_bib0345","doi-asserted-by":"crossref","first-page":"eaay5064","DOI":"10.1126\/sciadv.aay5064","article-title":"PHOTACs enable optical control of protein degradation","volume":"6","author":"Reynders","year":"2020","journal-title":"Sci. Adv."},{"issue":"4","key":"10.1016\/j.jsbmb.2021.105848_bib0350","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1080\/15548627.2020.1718362","article-title":"Targeting selective autophagy by AUTAC degraders","volume":"16","author":"Takahashi","year":"2020","journal-title":"Autophagy"},{"issue":"9","key":"10.1016\/j.jsbmb.2021.105848_bib0355","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1021\/acschembio.8b00693","article-title":"Homo-PROTACs for the Chemical Knockdown of Cereblon","volume":"13","author":"Steinebach","year":"2018","journal-title":"ACS Chem. Biol."},{"issue":"12","key":"10.1016\/j.jsbmb.2021.105848_bib0360","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1021\/acscentsci.6b00280","article-title":"Protein degradation by in-cell self-assembly of proteolysis targeting chimeras","volume":"2","author":"Lebraud","year":"2016","journal-title":"ACS Cent. Sci."},{"issue":"33","key":"10.1016\/j.jsbmb.2021.105848_bib0365","doi-asserted-by":"crossref","first-page":"9659","DOI":"10.1002\/anie.201503720","article-title":"Small-molecule-Mediated degradation of the androgen receptor through hydrophobic tagging","volume":"54","author":"Gustafson","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0370","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fendo.2018.00781","article-title":"Estrogen signaling in ER\u03b1-Negative breast Cancer: er\u03b2 and GPER","volume":"9","author":"Girgert","year":"2019","journal-title":"Front. Endocrinol. (Lausanne)."},{"issue":"8","key":"10.1016\/j.jsbmb.2021.105848_bib0375","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/nrc3093","article-title":"The different roles of ER subtypes in cancer biology and therapy","volume":"11","author":"Thomas","year":"2011","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.jsbmb.2021.105848_bib0380","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S1043-2760(98)00096-4","article-title":"ERbeta: a novel estrogen receptor offers the potential for new drug development","volume":"9","author":"Nilsson","year":"1998","journal-title":"Trends Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.jsbmb.2021.105848_bib0385","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0960-0760(00)00130-8","article-title":"Estrogen receptor beta in the breast: role\u3000in estrogen responsiveness and development of breast cancer","volume":"74","author":"Gustafsson","year":"2000","journal-title":"J.\u3000Steroid Biochem. Mol. Biol."},{"issue":"9","key":"10.1016\/j.jsbmb.2021.105848_bib0390","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1210\/endo.142.9.8395","article-title":"ER beta inhibits proliferation and invasion of breast cancer cell","volume":"142","author":"Lazennec","year":"2001","journal-title":"Endocrinol."},{"issue":"6","key":"10.1016\/j.jsbmb.2021.105848_bib0395","first-page":"2537","article-title":"Decreased expression of estrogen\u3000receptor protein in proliferative protein vasive mammary tumors","volume":"61","author":"Roger","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.jsbmb.2021.105848_bib0400","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.coph.2018.05.001","article-title":"Duality of estrogen receptor \u03b2 action in cancer progression","volume":"41","author":"Guillette","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"10.1016\/j.jsbmb.2021.105848_bib0405","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1210\/endo.143.3.8704","article-title":"Antagonists selective for estrogen receptor alpha","volume":"143","author":"Sun","year":"2002","journal-title":"Endocrinology"},{"issue":"1-2","key":"10.1016\/j.jsbmb.2021.105848_bib0410","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.mce.2009.08.030","article-title":"Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen","volume":"315","author":"Levy","year":"2010","journal-title":"Mol. Cell. Endocrinol."},{"issue":"7","key":"10.1016\/j.jsbmb.2021.105848_bib0415","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1111\/jphp.12908","article-title":"Synthesis and biological evaluation of novel cyclopropyl derivatives as subtype-selective ligands for estrogen receptor","volume":"70","author":"Wang","year":"2018","journal-title":"J. Pharm. Pharmacol."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076021000418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076021000418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:07:36Z","timestamp":1760746056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076021000418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":83,"alternative-id":["S0960076021000418"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105848","relation":{},"ISSN":["0960-0760"],"issn-type":[{"type":"print","value":"0960-0760"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective degradation of the estrogen receptor in the treatment of cancers","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2021.105848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105848"}}